Previous 10 | Next 10 |
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning! We’re at the midpoint of the week now and we’re still going strong with a look at the biggest pre-market stock movers for Wednesday. Source: Shutterstock There are loads to talk about tod...
RA Capital Management discloses ownership of ~5.75M shares of Catabasis Pharmaceuticals (CATB).It represents 7.5% passive ownership.Shares +44% during after market hours.Source For further details see: Catabasis Pharmaceuticals skyrockets 44% on 7.5% ownership disclosure by RA...
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview and provide information on its lead program QLS-215, which is in preclinical development for the treatmen...
Catabasis Pharmaceuticals (CATB): Q1 GAAP EPS of -$7.60 misses by $7.42.As of March 31, 2021, Catabasis had cash, cash equivalents and short-term investments of $146.9 million, compared to $44.9 million as of December 31, 2020.Press Release For further details see: Catabasis Pharmaceuti...
-- QLS-215, a Potential Best-in-Class Monoclonal Antibody Inhibitor of Plasma Kallikrein, Progresses in Preclinical Development for the Treatment of Hereditary Angioedema -- -- Strong Cash Position of $146.9M Planned to Fund IND-Enabling Studies, Phase 1a and Phase 1b/2 Clinic...
Gainers: [[GIFI]] +11.4%. [[SCOR]] +5.5%. [[AVNW]] +5.2%. [[NARI]] +4.6%. [[NTES]] +4.2%.Losers: [[CTLP]] -7.8%. [[FUTU]] -5.8%. [[ZLAB]] -5.7%. [[EVK]] -5.4%. [[CATB]] -3.3%. For further details see: GIFI, SCOR, CTLP and FUTU among after-hours movers
InvestorPlace - Stock Market News, Stock Advice & Trading Tips The bubble has burst. Penny stocks are falling like autumn leaves. The Reddit crowd and the day-trading community have learned a few difficult but needed lessons. First, it’s difficult to make money in the stock ma...
Catabasis Pharmaceuticals (CATB): FY GAAP EPS of -$2.03 misses by $0.20.Cash, cash equivalents and short-term investments of $44.9MPress Release For further details see: Catabasis Pharmaceuticals EPS misses by $0.20
-- Recently Completed Acquisition of Quellis Biosciences Includes QLS-215, a Potential Best-in-Class Monoclonal Antibody Inhibitor of Plasma Kallikrein in Preclinical Development for the Treatment of Hereditary Angioedema -- -- Proceeds from $110M Private Placement Planned to ...
Nova LifeStyle (NVFY) +231%.Siebert Financial (SIEB) +63% on Q4 results.Vir Biotechnology (VIR) +60% as its and GSK's COVID-19 antibody drug reduces hospitalization, death by 85%.OrganiGram Holdings (OGI) +40% on cannabis product deal with British American Tobacco.China HGS Rea...
News, Short Squeeze, Breakout and More Instantly...
Catabasis Pharmaceuticals Inc. Company Name:
CATB Stock Symbol:
NASDAQ Market:
Catabasis Pharmaceuticals Inc. Website:
-- Astria Reflects Company’s Patient-Focused Mission -- -- Promising Lead Program STAR-0215 is in Preclinical Development to Prevent Attacks in Hereditary Angioedema -- -- Company to Begin Trading Under New Ticker Symbol ATXS on September 9 -- Cataba...
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today reported financial results for the second quarter ended June 30, 2021 and provided a corporate update. “We are focused on advancing the development of our lead program, QLS-215, as a differe...